BackPerspective Therapeutics Overview
Perspective Therapeutics Inc

Perspective Therapeutics Target Price

Analysts' average 12-month price target for Perspective Therapeutics is $11.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.1

Average Target Price

$11.00254.8% upside

1 analysts in the last 4 months

High: $11 | Low: $11

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-18BMO Capital$11254.8% upsideOpen
2026-03-17Truist FinancialGreg Renza$12287.1% upsideOpen
2026-02-19Piper SandlerBiren Amin$16416.1% upsideOpen
2026-01-30H.C. Wainwright$12287.1% upsideOpen
2025-11-21UBSDavid Lai$7125.8% upsideOpen
2025-10-10BTIGJeet Mukherjee$14351.6% upsideOpen
2024-10-24UBSDavid Dai$20545.2% upsideOpen
2024-10-14OppenheimerJeff Jones$22609.7% upsideOpen
2024-09-25Truist FinancialNicole Germino$21577.4% upsideOpen
2024-07-25Bank of America SecuritiesAlec Stranahan$24674.2% upsideOpen
2024-06-18OppenheimerJeff Jones$19512.9% upsideOpen
2024-06-14RBC CapitalGregory Renza$33.2% downsideOpen
2024-05-15OppenheimerJeff Jones$235.5% downsideOpen

Perspective Therapeutics (CATX) FAQ

Perspective Therapeutics (CATX) currently reports a target price of $11. Use the charts on this page to explore Perspective Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Perspective Therapeutics is $11, about 254.8% upside from the current share price of $3.1. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $11, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Perspective Therapeutics, and consider following CATX for alerts when major investors trade the stock.

Perspective Therapeutics is classified in the Industrials sector. On target price, it currently shows $11. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing CATX with unrelated industries.